These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20118543)

  • 1. Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells.
    Kobayashi N; Seto K; Orikawa Y; Hamano H; Yoshinaga K; Takei M
    Biol Pharm Bull; 2010; 33(2):216-22. PubMed ID: 20118543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.
    Kato H; Seto K; Kobayashi N; Yoshinaga K; Meyer T; Takei M
    Life Sci; 2011 Oct; 89(17-18):603-8. PubMed ID: 21839751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
    Kawasaki D; Emori Y; Eta R; Iino Y; Hamano H; Yoshinaga K; Tanaka T; Takei M; Watson SA
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):883-92. PubMed ID: 17901954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Z-360 Suppresses Tumor Growth in MIA PaCa-2-bearing Mice
    Shiomi Y; Yoshimura M; Kuki K; Hori Y; Tanaka T
    Anticancer Res; 2017 Aug; 37(8):4127-4137. PubMed ID: 28739697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.
    Orikawa Y; Kato H; Seto K; Kobayashi N; Yoshinaga K; Hamano H; Hori Y; Meyer T; Takei M
    Mol Pain; 2010 Oct; 6():72. PubMed ID: 20979661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.
    Meyer T; Caplin ME; Palmer DH; Valle JW; Larvin M; Waters JS; Coxon F; Borbath I; Peeters M; Nagano E; Kato H
    Eur J Cancer; 2010 Feb; 46(3):526-33. PubMed ID: 20006921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical evaluation of a new orally-active CCK-2R antagonist, Z-360, in gastrointestinal cancer models.
    Grabowska AM; Morris TM; McKenzie AJ; Kumari R; Hamano H; Emori Y; Yoshinaga K; Watson SA
    Regul Pept; 2008 Feb; 146(1-3):46-57. PubMed ID: 17961733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
    Ali S; Ahmad A; Banerjee S; Padhye S; Dominiak K; Schaffert JM; Wang Z; Philip PA; Sarkar FH
    Cancer Res; 2010 May; 70(9):3606-17. PubMed ID: 20388782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
    Hong SK; Yang SY; Yin SH; Yang KX
    Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
    Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological evaluation of analgesic effects of the cholecystokinin2 receptor antagonist Z-360 in mouse models of formalin- and cancer-induced pain.
    Yoshinaga K; Horii T; Hamano H; Eta R; Ozaki T; Orikawa Y; Yoshii K; Kawabata Y; Hori Y; Seto K; Takei M; Kuraishi Y
    Biol Pharm Bull; 2010; 33(2):244-8. PubMed ID: 20118547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation.
    Jang SI; Fang S; Baek YY; Lee DH; Na K; Lee SY; Lee DK
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
    Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.
    Ueno M; Li CP; Ikeda M; Ishii H; Mizuno N; Yamaguchi T; Ioka T; Oh DY; Ichikawa W; Okusaka T; Matsuyama Y; Arai D; Chen LT; Park YS; Furuse J
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):307-315. PubMed ID: 28634650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.